NRBO
NeuroBo Pharmaceuticals, Inc. [NRBO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NRBO Stock Summary
In the News
NRBO Financial details
Company Rating
-
Market Cap
17.71M
Income
-12.55M
Revenue
4K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-23.08
Forward P/E
-
PEG
2.65
P/S
-
P/B
6.69
P/C
-
P/FCF
-1.86
Quick Ratio
5.47
Current Ratio
5.54
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.48
EPS next Y
-
EPS next Q
-
EPS this Y
-87.06%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
40%
-
-
-
-
SMA20
-
SMA50
-33.33%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-24%
ROE
-28%
ROC
-0.95%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.888-7.6
52W High
-66.29%
52W Low
+18%
RSI
27
Rel Volume
-
Avg Volume
1.37M
Volume
Perf Week
7.76%
Perf Month
-7.81%
Perf Quarter
-
Perf Half Y
-28.92%
-
-
-
-
Beta
-0.456
-
-
Volatility
0.29%, 0.25%
Prev Close
44.79%
Price
2.36
Change
42.17%
Company Profile
- Volume Average 1.37M
- Market Capitalization 17.71M
- Employee 8
- CEO Mr. Hyung-Heon Kim
- Headquarters Boston,MA,US
- IPO Date 2016-08-05
-
Website
https://www.neurobopharma.com 
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
